What Causes Poor Memory?

Memory difficulties—ranging from occasional forgetfulness to persistent, progressive impairment—can stem from a wide array of underlying causes. While age-related cognitive changes are common and often benign, significant or worsening memory problems warrant clinical evaluation to identify potentially treatable or serious conditions.

Reversible contributors include sleep disorders such as obstructive sleep apnea, which disrupts restorative slow-wave and REM sleep essential for memory consolidation; untreated depression and anxiety, which impair attention and encoding of new information; and chronic stress, which elevates cortisol levels and may adversely affect hippocampal function. Medication side effects—particularly from anticholinergics (e.g., certain antihistamines, tricyclic antidepressants, bladder antispasmodics), benzodiazepines, and some antiseizure drugs—can also produce transient memory deficits.

Medical conditions requiring prompt assessment include vitamin B12 deficiency, hypothyroidism, uncontrolled diabetes mellitus, chronic kidney or liver disease, and autoimmune encephalitis. Infections such as neurosyphilis or HIV-associated neurocognitive disorder, as well as structural brain abnormalities—including subdural hematoma, normal pressure hydrocephalus, or low-grade gliomas—must be considered, especially when memory decline presents with focal neurological signs or rapid progression.

Neurodegenerative disorders represent a major category of irreversible causes. Alzheimer’s disease is the most common etiology of progressive amnestic dementia, typically beginning with episodic memory loss and spreading to involve language, executive function, and visuospatial abilities. Other dementias—including frontotemporal dementia, dementia with Lewy bodies, and vascular dementia—may present with prominent memory impairment alongside distinctive behavioral, motor, or cerebrovascular features.

A thorough diagnostic workup generally includes a detailed history (with collateral input from family members), standardized cognitive testing (e.g., MoCA or MMSE), comprehensive metabolic panel, thyroid function tests, vitamin B12 and folate levels, syphilis serology, and structural neuroimaging (MRI preferred over CT). In select cases, cerebrospinal fluid analysis or amyloid PET imaging may be indicated to support biomarker-based diagnosis.

Early recognition and accurate diagnosis are critical—not only to initiate disease-modifying therapies where available (e.g., anti-amyloid monoclonal antibodies in early Alzheimer’s disease) but also to optimize supportive care, address safety concerns (e.g., driving, medication management), and facilitate advance care planning.